Please assess the completion status of the following clinical trial:

Trial Title: Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatoid arthritis (RA) per revised 1987 ACR criteria~* Active RA: ≥3 swollen and 3 tender joints with at least 1 swollen joint in the hand, excluding the PIP joint~* CRP \> 5.0 mg/L (RF and anti-CCP seronegative); CRP \>2 mg/l (RF and/or anti-CCP seropositive)~* DAS28 ≤ 5.1~* Stable regimen of concomitant RA therapy (NSAIDs, steroids, non- biological DMARDs).~* Negative PPD tuberculin skin test~Exclusion Criteria:~* Previous therapy with B or T cell depleting agents other than Rituximab (e.g. Campath). Prior treatment with Rituximab, TNF-inhibitors, other biologics (e.g. anti-IL-1 therapy) and systemic immunosuppressive agents is allowed with a washout period.~* Any history of ongoing, significant or recurring infections~* Any active inflammatory diseases other than RA~* Treatment with a systemic investigational drug within 6 months prior to screening~* Women of childbearing potential, unless receiving stable doses of methotrexate or leflunomide~* Significant cardiac or pulmonary disease (including methotrexate- associated lung toxicity)~* Hepatic or renal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: MOR103, experimental (Type: EXPERIMENTAL): Biological: MOR103 0.3 mg/kg or placebo
- Group 2: MOR103, experimental (Type: EXPERIMENTAL): Biological: MOR103 1.0 mg/kg or placebo
- Group 3: MOR103, experimental (Type: EXPERIMENTAL): Biological: MOR103 1.5 mg/kg or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).